Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. - Wikidata - awgldk - TriplyDB

Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials.

Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials.

http://www.wikidata.org/entity/Q35750598

about

Outcomes, outcomes, every where, nor any stop to think?LOST to follow-up Information in Trials (LOST-IT): a protocol on the potential impact Why Most Clinical Research Is Not Useful Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses Cholesterol confusion and statin controversy End points for comparative effectiveness research in heart failure Long-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studies Biased safety reporting in blinded randomized clinical trials: meta-analysis of angiotensin receptor blocker trials SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials Designing and analyzing clinical trials with composite outcomes: consideration of possible treatment differences between the individual outcomes Cholesterol paradox: a correlate does not a surrogate make.Delta inflation: a bias in the design of randomized controlled trials in critical care medicine.Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist.Impact of missing participant data for dichotomous outcomes on pooled effect estimates in systematic reviews: a protocol for a methodological study.A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes.Quality of reporting internal and external validity data from randomized controlled trials evaluating stents for percutaneous coronary intervention Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes.An optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.Testing for heterogeneity among the components of a binary composite outcome in a clinical trial Individual and composite study endpoints: separating the wheat from the chaff.Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients--a systematic review and meta-analysis.From short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertension Delphi-consensus weights for ischemic and bleeding events to be included in a composite outcome for RCTs in thrombosis prevention.Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges.Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.Outcomes in registered, ongoing randomized controlled trials of patient education.Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study A randomised controlled trial comparing standard or intensive management of reduced fetal movements after 36 weeks gestation--a feasibility study.Therapeutic innovations, diminishing returns, and control rate preservation Rethinking composite end points in clinical trials: insights from patients and trialists.Weighting components of composite end points in clinical trials: an approach using disability-adjusted life-years Analyzing composite outcomes in cardiovascular studies: traditional Cox proportional hazards versus quality-of-life-adjusted survival approaches.Effect of selenium supplementation on CD4 T-cell recovery, viral suppression, morbidity and quality of life of HIV-infected patients in Rwanda: study protocol for a randomized controlled trial.Improved delivery of cardiovascular care (IDOCC) through outreach facilitation: study protocol and implementation details of a cluster randomized controlled trial in primary care Endpoint selection and relative (versus absolute) risk reporting in published medication trials.Persistent organ dysfunction plus death: a novel, composite outcome measure for critical care trials Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Waking up from the DREAM of preventing diabetes with drugs.

P2860

Q24289467-4AB588AA-7BCF-4A74-BED6-B83BF74E41C6 Q24652537-ACD54B12-217E-4B99-AAB1-59A47E0253C3 Q24707972-2C6B5D26-9757-4F19-8BC4-EE3FCDDE1D52 Q26767278-861022C1-ECE3-4FA2-8D48-F67B866165D5 Q26801620-27913E13-B186-45C8-A3D9-19AB57D7009D Q27012843-6E31962B-1BDD-4AA1-87CB-79E9504E2B94 Q27027449-7B06D733-A593-43C7-9E20-10A9FFF745E2 Q28533725-535AC993-D602-41D9-BF25-FFF9EEFD32B2 Q28710019-58A166DC-181D-45D8-828E-2747BDA56D74 Q28730540-77F36D3B-89E9-438C-B5FA-3635E6D476CA Q30396673-C53E45C7-A492-49BB-BD4C-03250BC5612B Q30435820-CDFBC735-7414-4FC4-87A2-B47228BC3123 Q30860218-CAC2B1C8-415F-4E3E-A438-C8E48F0BD52F Q30871934-FC4C0CDC-8916-48A9-B409-8339A9F9F1C1 Q31105054-A6BF0002-723B-42A4-A47D-884C9435FE6A Q33428766-F35AF4A1-7546-4777-9EA4-8915BD8427EC Q33501445-10C536CF-AE18-419F-B935-49477020D7FA Q33569474-AE240F98-ED30-4C62-9A70-B372D0064FF7 Q33596793-1A3B8E95-0E69-4658-A847-5E2E6CC9B314 Q33606234-65A783D5-528D-4DC8-A25B-5CFB170902BE Q33646625-C5A46405-04E5-41E8-833C-C20EFD6DF79C Q33776201-B263F5AA-C544-4F3E-8364-79E30C5A4CDF Q33806102-85D4C240-4BA1-410A-92CA-9109D5632C83 Q33872146-C3668B06-4AF4-48C1-B695-6033ADC2E422 Q33900204-C52197EE-CAA6-484D-829B-00EA56F1AE53 Q34073347-BCD13805-FB58-4479-822E-657DEF7888A2 Q34142678-3921974B-0DCC-4CD1-8509-44D7188EEAAC Q34391137-6A8438EF-FF88-4D15-B1FD-A92E5047547C Q34567058-28C7741E-C8EB-4EE6-85C2-54955913FCA1 Q34670467-11E47D70-B99D-402C-A1A2-241996F6D7CF Q34712057-5C20276E-889F-4FA8-92ED-C69D48534B12 Q34766146-3F92798D-F215-4543-A233-9EE93992679E Q35029327-211769C7-2CB3-497B-8573-830194AC05B7 Q35049849-7379AD6C-589A-4B51-B257-251C0D0B772C Q35240769-A21DA79C-3309-4589-9741-96CA1AC80268 Q35397970-CB829B05-A3E2-4053-9806-C4593FAFD2F7 Q35527067-D9E4E24F-DE42-489C-91F9-01C825DC2205 Q35559489-D2003E8F-00F4-4FEB-96D6-C8A47116B4F8 Q35752562-464ACF91-A2B1-4FCC-9D83-F1D326FA1DE8 Q35763346-0ECCB1B8-DD6A-43E1-98ED-25E1CA02240D

P2860

Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials.

http://www.wikidata.org/entity/Q35750598

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Problems with use of composite ...... randomised controlled trials.

@ast

Problems with use of composite ...... randomised controlled trials.

@en

type

label

Problems with use of composite ...... randomised controlled trials.

@ast

Problems with use of composite ...... randomised controlled trials.

@en

prefLabel

Problems with use of composite ...... randomised controlled trials.

@ast

Problems with use of composite ...... randomised controlled trials.

@en

P1433

Q35750598-F4A8BE29-E7BD-44DB-B658-A2E7D5BA68E5

P1476

Q35750598-56491D39-57FB-4934-9EDA-47F0DA42281A

P2093

Q35750598-0E26253D-413E-4B2C-8904-A42A1D0D18DF

Q35750598-0FB53DA6-EC35-42E4-B8D1-362FAC7A4A0D

Q35750598-42FE0411-352E-4110-98B8-ADAC1A7BE7BE

Q35750598-675E2853-1DA4-4562-8AE8-4674981C8138

Q35750598-AC878EB6-439B-477B-B5FF-04BA45E7A6C8

Q35750598-AEEA3527-08A5-45EE-BA61-AFFED593CBAB

Q35750598-AF6CC1D2-564D-43F6-91E8-269D3E188362

Q35750598-B80E455C-4360-4DE0-B518-8919B911A2CE

Q35750598-C9DCD176-4CF0-40F2-BBD1-BAC808E73359

Q35750598-D291F3A9-8898-46D6-A58B-DF1139C8D8F6

P2860

Q35750598-756AF2F4-8771-4BFF-A7ED-974BD688A092

Q35750598-80322BDA-07D1-43C9-9616-07FAFF08E204

Q35750598-817818B8-62C9-4477-9839-536C60DC2FA1

Q35750598-8D7C09A3-4DCB-4AD2-84E3-199055AC3F09

Q35750598-8E040052-160E-4B7F-8769-72A0CB491C5C

Q35750598-A4533E1B-6D85-4B8D-B660-1C0316363976

Q35750598-C296EF4D-8DA3-4D66-8E8F-F05F668986D7

Q35750598-CD17EDEA-BA0F-4FF1-A4C0-DDDD37B25456

P304

Q35750598-740A8F34-ECA6-4D08-BCD0-E4BF7250040B

P31

Q35750598-13458B77-7D75-4153-B3B6-89DA816756DF

P356

Q35750598-8877AA49-F476-4109-81B1-B98C3A511AE5

P407

Q35750598-6972CBE0-9BF8-469B-AD91-51EF86CB59F3

P433

Q35750598-F7F98C8F-DBF5-44BB-ABE5-726CCED96836

P478

Q35750598-699B9F92-3B60-468A-90FB-8D21B66DB3F5

P50

Q35750598-19F28DF5-C1D4-405C-8C0C-9E0E695F27EA

Q35750598-4DCFFD08-EE3D-403E-91A0-B8B74ABBA5BF

Q35750598-7131F3F7-18A3-448F-9CBD-0F069CC4E3FC

Q35750598-95A4DD27-2D46-4902-A4B1-A722F2E0F930

Q35750598-A8129B86-CE72-4A5B-AC12-75F05794A821

Q35750598-C3C0480A-1FE6-4454-8EFE-0D14B12E04BA

Q35750598-E2A4F0E7-7A11-4F01-8D1C-C91C69C31C3C

P577

Q35750598-BE222DFD-846C-4683-9860-E46FFE63F121

P5875

Q35750598-648C8174-D68B-4476-BBEF-D46F3C57281D

P698

Q35750598-7AB5F464-12BA-4F86-A4D3-E8461C91F9C9

P921

Q35750598-FB0C43F1-BA40-4C68-814A-4418128B056D

P932

Q35750598-33BFEA07-91A7-4F9C-98AA-4D5539789794

P356

BMJ.39136.682083.AE

P1433

P1476

Problems with use of composite ...... randomised controlled trials.

@en

P2093

Andrew Worster

http://www.w3.org/2001/XMLSchema#string

Antònia Domingo-Salvany

http://www.w3.org/2001/XMLSchema#string

Diane Heels-Ansdell

http://www.w3.org/2001/XMLSchema#string

Edward J Mills

http://www.w3.org/2001/XMLSchema#string

Elie A Akl

http://www.w3.org/2001/XMLSchema#string

Gaietà Permanyer-Miralda

http://www.w3.org/2001/XMLSchema#string

Holger J Schünemann

http://www.w3.org/2001/XMLSchema#string

Ignacio Ferreira-González

http://www.w3.org/2001/XMLSchema#string

Jordi Alonso

http://www.w3.org/2001/XMLSchema#string

Pablo Alonso-Coello

http://www.w3.org/2001/XMLSchema#string

P2860

Measuring inconsistency in meta-analyses

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

One thousand health-related quality-of-life estimates.

Lessons learned from recent cardiovascular clinical trials: Part I.

Composite outcomes in randomized trials: greater precision but with greater uncertainty?

Validity of composite end points in clinical trials.

Combined endpoints: can we use them?

A method of assigning scores to the components of a composite outcome: an example from the MITI trial.

P304

786

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.39136.682083.AE

http://www.w3.org/2001/XMLSchema#string

P407

P433

7597

http://www.w3.org/2001/XMLSchema#string

P478

334

http://www.w3.org/2001/XMLSchema#string

P50

Pablo Alonso-Coello

Diane Heels-Ansdell

Dianne M Bryant

Victor M. Montori

P577

2007-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51385265

http://www.w3.org/2001/XMLSchema#string

P698

17403713

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

1852019

http://www.w3.org/2001/XMLSchema#string